Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a safety study of ritlecitinib in adults with alopecia areata
2020-001509-21Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing Ritlecitinib with Placebo (2 arms). Primary endpoint: Change from baseline in I-V interwave latency on BAEP at 80 dB at Month 9. Started Jun 2021; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2020-001509-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001509-21.